Steven C. Berger
Keine laufenden Positionen mehr
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Brian Posner | M | 62 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 5 Jahre |
David Ian Johnson | M | 66 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Amit Singh Dang | M | 43 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 Jahre |
Nachum Stein | M | 75 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 1 Jahre |
Yaron Conforti | M | 44 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Jerome Zeldis | M | 74 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 5 Jahre |
Dave Stefansky | M | 52 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 4 Jahre |
Mike M. Goldberg | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 1 Jahre |
Joseph M. Leone | M | 70 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Jeffrey Sklar | M | 61 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Kenneth D. Pearsen | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 3 Jahre |
Joseph Sierchio | M | 74 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 4 Jahre |
Dennis Bennie | M | - |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Richard Rosenblum | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 Jahre |
James Sapirstein | M | 63 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 2 Jahre |
Kenneth Londoner | M | 57 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 2 Jahre |
Hank Cohn | M | 52 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 3 Jahre |
S. Lawrence Prendergast | M | 83 |
LaBranche & Co., Inc.
LaBranche & Co., Inc. Investment Banks/BrokersFinance LaBranche & Co., Inc. provides securities execution and brokerage services to institutional investors and professional traders. The company was founded by George M.L. LaBranche Jr. in 1924 and is headquartered in New York, NY. | 6 Jahre |
Bradford C. Barton | M | 64 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 5 Jahre |
Matthew Lerner | M | 42 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Javier Jimenez | M | 58 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 3 Jahre |
Laura Rivers-Bowerman | F | - |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Jatinder Bhogal | M | 56 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 2 Jahre |
Carmelo Marrelli | M | 53 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Jeffrey A. Mandel | M | - |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 3 Jahre |
Mark Billings | M | 54 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Andrew G. Day | M | 59 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 3 Jahre |
Timothy O. Searcy | M | 55 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 1 Jahre |
Mazen Haddad | M | 51 |
Goldbard Capital Corp.
Goldbard Capital Corp. Financial ConglomeratesFinance Goldbard Capital Corp. is a Capital Pool Company. The company is engaged in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It was founded on June 11, 2007 and is headquartered in Toronto, Canada. | 3 Jahre |
Joseph Laudano | M | - |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 20 | 66,67% |
Kanada | 10 | 33,33% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Steven C. Berger
- Persönliches Netzwerk